| Code | CSB-RA003995MB5HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar to Eculizumab-AAGH, designed to target complement component 5 (C5), a critical protein in the complement cascade of the innate immune system. C5 plays a pivotal role in immune defense by facilitating the formation of the membrane attack complex (MAC) and generating the potent anaphylatoxin C5a. Dysregulated C5 activation contributes to various complement-mediated disorders, including paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and myasthenia gravis. By binding to C5, this antibody prevents its cleavage into C5a and C5b, thereby inhibiting downstream complement activation and inflammation.
The reference antibody Eculizumab-AAGH is an FDA-approved therapeutic agent that has demonstrated clinical efficacy in treating complement-driven diseases. This biosimilar provides researchers with a valuable tool for investigating complement system biology, exploring disease mechanisms involving C5-mediated pathology, and developing novel therapeutic strategies. It is particularly useful for in vitro and in vivo studies examining complement inhibition, inflammatory responses, and immune-mediated tissue damage.
There are currently no reviews for this product.